Ind-Swift Laboratories's EBIT per Share for the
three
months ended in Mar. 2026 was ₹1.45.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.96.
During the past 3 years, the average EBIT per Share Growth Rate was -61.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ind-Swift Laboratories's EBIT per Share or its related term are showing as below:
NSE:INDSWFTLAB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -77.7 Med: 13.85 Max: 153.4
Current: -61.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Ind-Swift Laboratories was 153.40% per year. The lowest was -77.70% per year. And the median was 13.85% per year.
NSE:INDSWFTLAB's 3-Year EBIT Growth Rate is ranked worse than 97.16% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs NSE:INDSWFTLAB: -61.90
Ind-Swift Laboratories (NSE:INDSWFTLAB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ind-Swift Laboratories EBIT per Share Related Terms
Ind-Swift Laboratories EBIT per Share Historical Data
* Premium members only.
The historical data trend for Ind-Swift Laboratories's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.96
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a EBIT per Share of ₹4.96 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ind-Swift Laboratories and its competitors. According to the industry distribution chart, Ind-Swift Laboratories ranks #787 out of 810 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is Ind-Swift Laboratories' EBIT per Share too high?
Ind-Swift Laboratories' current EBIT per Share is ₹4.96. Based on the distribution chart, Ind-Swift Laboratories ranks #787 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ind-Swift Laboratories has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ind-Swift Laboratories ranks #787 out of 810 companies for EBIT per Share. This places Ind-Swift Laboratories in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ind-Swift Laboratories and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ind-Swift Laboratories's current EBIT per Share is ₹4.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹36.89, compared to a current price of ₹225.47 — trading 511.2% above its estimated fair value. The current EBIT per Share is ₹4.96. Ind-Swift Laboratories' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current EBIT per Share is ₹4.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹225.47 is trading 511.2% above its estimated GF Value™ of ₹36.89.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:INDSWFTLAB:
EBIT per Share: ₹4.96
GF Value™: ₹36.89 vs. price of ₹225.47 (511.2% above fair value)
No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
48GF Score
Get the complete analysis for NSE:INDSWFTLAB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDSWFTLAB has been successfully added to your 
